# BioReason-Pro RL Review: Myc (mouse)

Source: Myc-deep-research-bioreason-rl.md

- **Correctness**: 4/5
- **Completeness**: 3/5

## Analysis

BioReason produces a solid analysis of Myc as a bHLH-Zip transcription factor. The domain architecture is correctly identified, the molecular function inference is accurate, and the mechanistic model (E-box binding, coactivator recruitment, growth/proliferation gene programs) is sound. This is a case where the domain architecture strongly constrains function and BioReason performs well.

Note: The curated Myc review is at INITIALIZED status (all annotations PENDING), so comparison is against GOA annotations and known biology.

### What was right

| Aspect | BioReason claim | GOA annotations |
|--------|----------------|-----------------|
| bHLH-Zip transcription factor | Correct | DNA-binding TF activity (GO:0003700, GO:0000981) |
| RNA Pol II cis-regulatory binding (GO:0000978) | Correct | IBA-annotated |
| E-box DNA binding | Correct | Sequence-specific DNA binding |
| Nuclear localization | Correct | Nucleus (GO:0005634) IBA/IEA-annotated |
| Positive regulation of transcription | Correct | Regulation of transcription by RNAPII (GO:0006357) |
| Positive regulation of cell proliferation | Correct | GO:0008284, IBA-annotated |
| Coactivator recruitment (TRRAP, HATs) | Correct | Well-established mechanism |
| Protein dimerization | Implied (bHLH-Zip) | GO:0046983, IEA-annotated |

### What was partially right

- **"Transcriptional activator" framing is incomplete**: While Myc is primarily an activator, it also represses transcription at specific targets. The GOA includes negative regulation of transcription by RNAPII (GO:0000122, ISO). BioReason mentions only positive regulation.
- **Chromatin remodeling is mentioned but not elaborated**: BioReason correctly notes histone acetyltransferase recruitment but does not mention Myc's role in transcriptional pause release (P-TEFb recruitment) or global transcriptional amplification.

### What was wrong or misleading

- **No mention of Max as obligate partner**: The GOA includes Myc-Max complex (GO:0071943) as an IBA annotation. Max is the essential dimerization partner for Myc's DNA-binding activity. BioReason mentions "other bHLH-zipper transcription factors" generically but never names Max. This is a significant omission for understanding Myc biology.

### Major omissions

- **Max dimerization**: Myc cannot bind DNA as a monomer; it requires heterodimerization with Max. This is fundamental.
- **Myc-Max complex (GO:0071943)**: IBA-annotated CC term, not discussed.
- **Apoptotic function**: Myc is a potent inducer of apoptosis when survival signals are absent. The GOA includes extensive apoptosis-related terms (GO:0006915, GO:0043065, GO:0097190). Not mentioned.
- **Nucleolus localization (GO:0005730)**: Myc regulates ribosomal RNA transcription and localizes to nucleoli. Not mentioned.
- **G1/S cell cycle transition (GO:0000082)**: ISO-annotated. Myc drives the G1/S transition through cyclin D and CDK regulation. Not mentioned.
- **Ribosome biogenesis**: A major Myc target gene program. Not mentioned.
- **Metabolic reprogramming**: Myc drives glycolysis, glutaminolysis, and lipid synthesis. Not mentioned.
- **Oncogenic role**: Myc is one of the most commonly deregulated oncogenes. Not discussed.
- **Ubiquitin-mediated degradation**: Myc has a very short half-life (~20-30 min) regulated by ubiquitin ligases (Fbxw7, Skp2). GOA includes ubiquitin protein ligase binding (GO:0031625). Not mentioned.
- **Multiple isoforms**: The curated review notes three alternative products (c-myc 1, c-myc 2, isoform 3). Not mentioned by BioReason.

### Failure modes observed

- **Missing obligate partner biology**: The Myc-Max interaction is not optional -- it is required for DNA binding. Failing to mention Max is like describing a heterodimeric enzyme without mentioning one of its subunits.
- **Activation-only bias**: The system infers "positive regulation" from the N-terminal activation domain but misses the well-documented repressive and apoptotic functions. This is a one-sided reading of the domain architecture.
- **No pathway context**: Myc sits at the convergence of multiple signaling pathways (Wnt, Notch, RTK/MAPK) and its expression is tightly regulated. None of this upstream context is captured.

## Cross-gene summary

| Gene | Correctness | Completeness | Primary failure mode |
|------|-------------|--------------|---------------------|
| Calm1 | 3/5 | 2/5 | Superficial -- stopped at obvious Ca2+ binding |
| Ctnnb1 | 4/5 | 3/5 | Hedging on well-known Wnt biology |
| Egfr | 5/5 | 3/5 | Domain-accurate but biologically generic |
| Fyn | 4/5 | 2/5 | Fold-bias -- generic SFK, not Fyn-specific |
| Myc | 4/5 | 3/5 | Missing obligate partner (Max) and dual function |

**Recurring pattern**: BioReason excels at structural domain analysis and basic molecular function inference but consistently fails to capture (1) specific binding partners, (2) tissue-specific biology, (3) regulatory mechanisms, and (4) the distinction between core and peripheral functions. The GO term lists are often extensive but disconnected from the reasoning -- terms appear to be propagated from InterPro2GO mappings without being integrated into the functional narrative.
